Company profile for EQRx

NEW Drugs in Dev: 4
PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

EQRx is committed to making innovative medicines at dramatically lower prices for the benefit of people and society. By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the company seeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before. Headquartered in Cambridge, Massachu...
EQRx is committed to making innovative medicines at dramatically lower prices for the benefit of people and society. By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the company seeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before. Headquartered in Cambridge, Massachusetts, the company is backed by GV, ARCH Venture Partners, Andreessen Horowitz, Casdin Capital, Section 32, Nextech, and Arboretum Ventures.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
50 Hampshire St, Cambridge, Massachusetts 02139, US
Telephone
Telephone
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more
The unraveling of EQRx’s low-cost drug dream
The unraveling of EQRx’s low-cost drug dream

05 Oct 2023

// Annalee Armstrong FIERCE BIOTECH

https://www.fiercebiotech.com/biotech/unraveling-eqrxs-low-cost-drug-dream

Annalee Armstrong FIERCE BIOTECH
05 Oct 2023

https://endpts.com/eqrx-had-limited-buyer-interest-tried-acquiring-other-companies-before-revolution-came-for-its-cash/

Kyle LaHucik ENDPTS
04 Oct 2023
Lynk’s JAK1 inhibitor improves severity, itching in eczema study
Lynk’s JAK1 inhibitor improves severity, itching in eczema study

09 Aug 2023

// Gabrielle Masson FIERCE BIOTECH

https://www.fiercebiotech.com/biotech/after-eqrx-partnership-falls-apart-lynks-mid-stage-eczema-trial-hits-main-goals

Gabrielle Masson FIERCE BIOTECH
09 Aug 2023

https://endpts.com/eqrx-acquired-by-revolution-medicines-another-alexis-borisy-company-in-all-stock-deal/

Max Gelman ENDPTS
01 Aug 2023
EQRx's low cost drug dream ends in Revolution
EQRx's low cost drug dream ends in Revolution

01 Aug 2023

// James Waldron FIERCE BIOTECH

https://www.fiercebiotech.com/biotech/eqrxs-dream-dies-revolution-spies-opportunity-add-1b-its-balance-sheet

James Waldron FIERCE BIOTECH
01 Aug 2023

https://www.globenewswire.com/news-release/2023/08/01/2715636/0/en/Revolution-Medicines-Inc-to-Acquire-EQRx-Inc-in-All-Stock-Transaction-to-Gain-More-Than-1-Billion-in-Additional-Capital.html

GLOBENEWSWIRE
01 Aug 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty